Skip to main content

Table 6 OS and PFS (IP group)

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

  Median OS (months) Median PFS (months)
Protein Expression Low High P-value Low High P-value
 ERCC1 20.2 8.6 0.114 20.2 3.9 0.045
 COX2 15.4 8.6 0.106 5.1 2.9 0.362
 Tubulin B3 5.4 10.6 0.349 4.9 3.9 0.419
 CD4 8.6 3.6 0.946 4.9 2.8 0.81
 CD8 8.6 15.4 0.919 4.9 3.9 0.924
SNPs         
 MDR1 C3435T CC TT CT P-value CC TT CT P-value
  13.5 15.4 8.2 0.318 8.5 4.9 2.8 0.374
 MDR1 G2677 T GG TT GT   GG TT GT  
  8.2 3.6 15.4 0.104 3.9 2.8 12 0.041
 ERCC1C8092A AA CC CA   AA CC CA  
  3.6 8.6 15.4 0.14 0.9 3.9 5.1 0.008
 ERCC1 N118 N CC TT CT   CC TT CT  
  8.2 10.6 8.5 0.394 5.1 6.4 3.9 0.195